T. Rowe Price Investment Management
BPMC

T. Rowe Price Investment Management’s Blueprint Medicines BPMC Stock Holding History

T. Rowe Price Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,302,810
Closed -$115M – 692
2025
Q1 		$115M Buy
1,302,810
+605,783
+87% +$59.1M 0.08% 252
2024
Q4 		$60.8M Sell
697,027
-51,665
-7% -$4.73M 0.04% 377
2024
Q3 		$69.3M Sell
748,692
-43,026
-5% -$4.27M 0.04% 354
2024
Q2 		$85.3M Sell
791,718
-211,478
-21% -$21.2M 0.05% 306
2024
Q1 		$95.2M Sell
1,003,196
-595,593
-37% -$51.1M 0.06% 295
2023
Q4 		$147M Sell
1,598,789
-859,380
-35% -$55.7M 0.1% 222
2023
Q3 		$123M Buy
2,458,169
+7,134
+0.3% +$381K 0.09% 237
2023
Q2 		$155M Sell
2,451,035
-35,915
-1% -$1.95M 0.11% 211
2023
Q1 		$112M Sell
2,486,950
-5,431
-0.2% -$245K 0.08% 241
2022
Q4 		$109M Buy
2,492,381
+233,624
+10% +$11.2M 0.08% 242
2022
Q3 		$149M Buy
+2,258,757
New +$145M 0.12% 180

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management's BPMC Position: Q2 2025 in Review

T. Rowe Price Investment Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 1,302,810 shares — an estimated $115M sold.

T. Rowe Price Investment Management first reported a position in BPMC in Q3 2022 and held it in 11 quarters. The position peaked at $155M in Q2 2023. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • T. Rowe Price Investment Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,302,810 Blueprint Medicines shares in Q2 2025, an estimated $115M.
  • T. Rowe Price Investment Management first reported a position in Blueprint Medicines in Q3 2022 and held it in 11 quarters.
  • T. Rowe Price Investment Management's Blueprint Medicines position peaked at $155M in Q2 2023.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.